Ascentage Pharma Group International (NASDAQ:AAPG) Earns Overweight Rating from Analysts at JPMorgan Chase & Co.

Stock analysts at JPMorgan Chase & Co. began coverage on shares of Ascentage Pharma Group International (NASDAQ:AAPG) in a research report issued on Thursday,Briefing.com Automated Import reports. The firm set an “overweight” rating on the stock.

Ascentage Pharma Group International Trading Down 0.5 %

Ascentage Pharma Group International stock opened at $18.37 on Thursday. Ascentage Pharma Group International has a fifty-two week low of $16.50 and a fifty-two week high of $21.40.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.